A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection (NCT06016088)
RESPIR-102
This trial is Currently recruiting
Registration number NCT06016088
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Peter Wark
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.